Dupilumab改善中重度特应性皮炎成人患者生活质量:随机安慰剂对照临床试验结果
该随机双盲安慰剂对照IIa期试验纳入64例中重度特应性皮炎成人,评估每周300mg皮下注射Dupilumab或安慰剂12周对健康相关生活质量(QoLIAD)的影响。
要点
- Dupilumab每周300mg皮下注射12周显著改善中重度特应性皮炎成人QoLIAD评分。
- QoLIAD改善与EASI、瘙痒NRS、5维瘙痒、SCORAD及睡眠/瘙痒VAS变化显著相关。
- 生活质量改善与临床疗效指标变化一致,支持Dupilumab的综合获益。
核心结论
- Dupilumab改善中重度特应性皮炎成人QoLIAD评分,且与疗效指标改善显著相关。
研究设计与样本
- 随机、双盲、安慰剂对照IIa期试验(NCT01548404),64例中重度特应性皮炎成人随机接受每周300mg皮下Dupilumab或安慰剂12周。
临床怎么用
- Dupilumab治疗中重度特应性皮炎成人可显著改善生活质量,且生活质量改善与皮损及瘙痒改善相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab, a human anti-interleukin-4 receptor alpha monoclonal antibody, significantly improved clinical signs and symptoms in adults with moderate-to-severe atopic dermatitis in a randomized, double-blind, placebo-controlled, phase IIa trial. OBJECTIVES: We evaluate health-related quality of life (HRQoL) and correlation of HRQoL with secondary clinical and patient-reported outcomes in a subset of patients from this trial of dupilumab. METHODS: Patients were randomized to 300 mg weekly subcutaneous dupilumab or placebo for 12 weeks (trial registration: NCT01548404). The Quality of Life Index of Atopic Dermatitis (QoLIAD) score (exploratory outcome) and its correlation with efficacy outcomes [Eczema Area and Severity Index (EASI); primary end point; SCORing Atopic Dermatitis (SCORAD), SCORAD visual analogue scale (VAS) scores for sleep and pruritus, pruritus numerical rating scale (NRS) and 5-dimensional pruritus] were assessed in 64 adults with moderate-to-severe atopic dermatitis. RESULTS: Mean QoLIAD scores at baseline ± standard error (SE) were 13·3 ± 1·34 and 11·3 ± 1·09 for the placebo and dupilumab groups, respectively. Dupilumab significantly improved QoLIAD score after 12 weeks of treatment vs. placebo (mean % change from baseline in QoLIAD score ± SE: -64·0 ± 6·91 vs. -11·1 ± 9·31). Least squares mean % difference from baseline vs. placebo in QoLIAD score ±SE was -52·0 ± 11·43, P < 0·001). QoLIAD scores significantly correlated with changes in efficacy outcomes, including EASI (r = 0·44), 5-dimensional pruritus (r = 0·49), pruritus NRS (r = 0·41), total SCORAD (r = 0·56) and SCORAD VAS scores for sleep (r = 0·47) and pruritus (r = 0·54); all P < 0·05. CONCLUSIONS: Dupilumab improved QoLIAD scores in adults with atopic dermatitis and was significantly associated with improvements in study outcomes.
引用
- Tsianakas A, Luger TA, Radin A, et al. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol. 2018. PMID: 28845523. doi:10.1111/bjd.15905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。